Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2024

This “Chemotherapy-induced neutropenia - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chemotherapy-induced neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chemotherapy-induced neutropenia Understanding

Chemotherapy-induced neutropenia: Overview

Chemotherapy-induced neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. The incidences of CIN and its complications, such as fever, infection, and chemotherapy dose alterations, vary by type of malignancy. One large prospective registry reported CIN rates of 15% to 65% in patients with five major tumor types: breast cancer, colon cancer, lymphoma, lung cancer, and ovarian cancer. The rates of FN ranged from 7% to 30%.

Chemotherapy-induced neutropenia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy-induced neutropenia pipeline landscape is provided which includes the disease overview and Chemotherapy-induced neutropenia treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy-induced neutropenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy-induced neutropenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy-induced neutropenia R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy-induced neutropenia.

Chemotherapy-induced neutropenia Emerging Drugs Chapters

This segment of the Chemotherapy-induced neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chemotherapy-induced neutropenia Emerging Drugs

Plinabulin: Beyond Spring Pharmaceuticals Plinabulin, BeyondSpring’s lead drug, is a selective immunomodulating microtubule-binding agent (SIMBA). It is a novel, intravenous infused, patent-protected drug that is NDA filed for CIN prevention in the U.S. and China and has a fully enrolled pivotal Phase 3 anti-cancer study for non-small cell lung cancer (NSCLC). Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells, and the second is early-onset action in CIN prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs). Plinabulin received breakthrough designation from both U.S. and China FDA for CIN prevention indication. As a “pipeline in a drug,” plinabulin is being broadly studied in various immuno-oncology regimens to determine if it can boost the effects of the PD-1/PD-L1 antibodies and re-sensitize PD-1/PD-L1 antibody resistantpatients.

EC-18: Enzychem Lifesciences EC-18 is the company’s proprietary compound originally derived from Sika deer antler, which acts as Pattern Recognition Receptors (PRR) (e.g., TLR4) endocytic trafficking accelerator contributing to swift removal of PAMPs/DAMPs. For acute respiratory distress syndrome associated with COVID-19, dysregulation of the TLRs signaling pathway is reported to be relevant. With this unique mechanism of action, the company is developing EC-18 for indications including chemoradiation induced oral mucositis (CRIOM), chemotherapy induced neutropenia (CIN) and acute radiation syndrome(ARS).

Chemotherapy-induced neutropenia: Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy-induced neutropenia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chemotherapy-induced neutropenia

There are approx. 4+ key companies which are developing the therapies for Chemotherapy-induced neutropenia. The companies which have their Chemotherapy-induced neutropenia drug candidates in the most advanced stage, i.e. preregistration include, Beyond SpringPharmaceuticals.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chemotherapy-induced neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chemotherapy-induced neutropenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy-induced neutropenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy-induced neutropenia drugs.

Chemotherapy-induced neutropenia Report Insights

• Chemotherapy-induced neutropenia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chemotherapy-induced neutropenia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chemotherapy-induced neutropenia drugs?
• How many Chemotherapy-induced neutropenia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy-induced neutropenia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy-induced neutropenia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chemotherapy-induced neutropenia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Beyond SpringPharmaceuticals
• Enzychem Lifesciences
• Tianjin Sino BiotechLtd.
• Evive Biotech

Key Products

• Plinabulin
• EC-18
• rHSA-GCSF
• Ryzneuta

This product will be delivered within 2 business days.